Masoud Tavazoie, M.D., Ph.D.
Chief Executive Officer & Co-founder
Masoud is co-founder, Board Director, and the Chief Executive Officer of Rgenix.
David Darst, M.B.A.
CHIEF OPERATING OFFICER
David co-leads Rgenix’s financing, corporate development, and drug development efforts.
Roger Waltzman, M.D., M.B.A.
Chief Medical Officer
Roger is a Board-certified Medical Oncologist with over 20 years of experience.
Stephen Wald
VP of Chemistry & Pharmaceutical Sciences
Steve is responsible for chemical, analytical and formulation development, and manufacturing scale-up, of Rgenix’s drug candidates.
Isabel Kurth, Ph.D.
VP of Research
Isabel has authored numerous book chapters and international reviews, and her research discoveries were published in leading journals.
Foster Gonsalves, Ph.D., M.P.H.
VP of Drug Development & Strategy
Foster heads preclinical development at Rgenix. Prior to joining Rgenix, Foster was a management consultant within the life sciences practice
Corey Sohmer, M.B.A.
VP of Finance & Accounting
Corey brings to Rgenix more than 25 years of progressive leadership experience in finance and accounting.
Michael Szarek, Ph.D.
VP of Clinical & Regulatory Affairs
Michael leads clinical and regulatory affairs at Rgenix.